How much funding has Alnylam Pharmaceuticals raised?

Alnylam Pharmaceuticals has raised $1.0B in total funding, most recently a Corporate Round.

Who are Alnylam Pharmaceuticals's investors?

Alnylam Pharmaceuticals's investors include Blackstone.

When was Alnylam Pharmaceuticals founded?

Alnylam Pharmaceuticals was founded in 2002.

Where is Alnylam Pharmaceuticals headquartered?

Alnylam Pharmaceuticals is headquartered in Cambridge, Massachusetts, United States.

What industry is Alnylam Pharmaceuticals in?

Alnylam Pharmaceuticals operates in Biotech, Genomics, Healthcare, Therapeutics.

How many employees does Alnylam Pharmaceuticals have?

Alnylam Pharmaceuticals has 1001-5000 employees.

Alnylam Pharmaceuticals

IPO

SILENCE DISEASE. AMPLIFY LIFE.

Public · Cambridge, United States · Founded 2002 · $1.0B raised

Headquarters: Cambridge, Massachusetts
Employees: 1001–5000
Founded: 2002
Business Model: B2B
Website: alnylam.com

Total Funding: $1.0B
Last Round: $1.0B Corporate RoundApr 2020
Rounds: 3
Type: Public

About

Alnylam Pharmaceuticals is the pioneer and global leader in RNA interference (RNAi) therapeutics, having discovered the mechanism and translated it into six FDA-approved medicines since 2018. The company develops small interfering RNA (siRNA) drugs that silence disease-causing genes at their source, targeting rare diseases, cardiovascular disease, and neurological conditions. Headquartered in Cambridge, Massachusetts, Alnylam employs 2,500+ people and operates globally across six continents.

Summary

Alnylam Pharmaceuticals is a Biotech company based in Cambridge, United States, founded in 2002. It has raised $1.0B in total across 3 rounds, most recently a $1.0B Corporate Round round in Apr 2020. Investors include Blackstone.

LinkedIn X (Twitter)